IBSA UK&I Newsroom

IBSA UK launches non-hormonal injectable for menopausal vulvovaginal symptoms

A next-generation hyaluronic acid treatment designed to improve sexual and genital symptoms of GSM Watford, UK. February 2nd 2026 – IBSA UK, the UK subsidiary of Swiss pharmaceutical company IBSA, today announces the launch of Hyaluxelle®, a non-hormonal hyaluronic acid treatment indicated for adult women to treat vulvar vestibule atrophic

IBSA UK&I launches Perovial®: the first licensed injectable option for men with acute Peyronie’s disease

A clinically supported option for early intervention in a historically underdiagnosed and undertreated condition. WATFORD, UK. February 2nd, 2026 – IBSA UK&I has today announced the launch of Perovial®, the first licensed hyaluronic acid injectable indicated for the management of Peyronie’s disease (PD) in its acute phase. Perovial® offers healthcare

Join the 10,000+ businesses that already use PR Fire today!

Book a discovery call
The Fairground, Andover SP11 0QN
hello@prfire.com
Join our mailing list

Linkedin Instagram Facebook Youtube

PR Fire UK PR Fire US

Campaigns

Christmas PR
Black Friday PR
International Distribution
PR Writing Bundles
Distribution Bundles
Media Bundles

Business

Frequently Asked Questions
Cookie Policy
Terms of Use
Editorial Guidelines
PR Distribution Policy
Privacy Policy